• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评论：食管癌切除术后辅助免疫治疗的真实世界见解

Commentary: Real-World Insights into Adjuvant Immunotherapy after Esophagectomy.

作者信息

Hong Min Hee

机构信息

Department of Medical Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

出版信息

J Chest Surg. 2025 Jul 5;58(4):146-147. doi: 10.5090/jcs.25.065.

DOI:10.5090/jcs.25.065
PMID:40589060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12230685/
Abstract

See Article page 134.

摘要

见第134页文章。

相似文献

1
Commentary: Real-World Insights into Adjuvant Immunotherapy after Esophagectomy.评论：食管癌切除术后辅助免疫治疗的真实世界见解
J Chest Surg. 2025 Jul 5;58(4):146-147. doi: 10.5090/jcs.25.065.
2
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study.新辅助免疫化疗及食管切除术后辅助免疫治疗食管鳞状细胞癌：一项真实世界研究
Front Immunol. 2024 Dec 17;15:1456193. doi: 10.3389/fimmu.2024.1456193. eCollection 2024.
3
Adjuvant Therapy for Patients with a Tumor-Positive Resection Margin After Neoadjuvant Chemoradiotherapy and Esophagectomy.新辅助放化疗和食管切除术后肿瘤阳性切缘患者的辅助治疗。
Ann Surg Oncol. 2024 Jun;31(6):3813-3818. doi: 10.1245/s10434-024-14912-x. Epub 2024 Jan 20.
4
Surgical Approach to Esophagectomy Post CheckMate 577: Do Lymph Nodes Matter if Everyone Gets Adjuvant Immunotherapy?CheckMate 577 术后食管癌切除术的手术入路：如果每个人都接受辅助免疫治疗，那么淋巴结重要吗？
Thorac Surg Clin. 2023 May;33(2):209-213. doi: 10.1016/j.thorsurg.2023.01.002. Epub 2023 Feb 26.
5
Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study.评估辅助化疗对食管鳞状细胞癌食管切除术后偶然发现淋巴结阳性的cT1b-T2患者的疗效：一项回顾性队列研究。
BMC Cancer. 2025 Jul 1;25(1):1060. doi: 10.1186/s12885-025-14472-7.
6
Adjuvant Immunotherapy in Curative Intent Esophageal Cancer Resection Patients: Real-World Experience within an Integrated Health System.根治性食管癌切除患者的辅助免疫治疗：综合医疗系统中的真实世界经验
Cancers (Basel). 2023 Nov 7;15(22):5317. doi: 10.3390/cancers15225317.
7
Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.食管癌同步放化疗后联合免疫治疗行食管癌切除术的安全性和可行性。
J Thorac Cardiovasc Surg. 2021 Mar;161(3):836-843.e1. doi: 10.1016/j.jtcvs.2020.11.106. Epub 2020 Dec 17.
8
Commentary: Induction immunotherapy for esophageal cancer: A safe start.
J Thorac Cardiovasc Surg. 2021 Mar;161(3):844. doi: 10.1016/j.jtcvs.2020.12.027. Epub 2021 Jan 13.
9
Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.使用MAGE肽脉冲处理的树突状细胞进行免疫治疗后，食管原发性恶性黑色素瘤患者中肽特异性免疫反应的诱导。
Jpn J Clin Oncol. 2007 Feb;37(2):140-5. doi: 10.1093/jjco/hyl136. Epub 2007 Jan 25.
10
Commentary: Is neoadjuvant chemoimmunotherapy for esophageal cancer the next great frontier?
J Thorac Cardiovasc Surg. 2024 Aug;168(2):429-430. doi: 10.1016/j.jtcvs.2024.01.025. Epub 2024 Jan 20.

本文引用的文献

1
Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan.接受手术切除的食管癌辅助免疫治疗的初步真实世界疗效：一项来自台湾的回顾性研究
J Chest Surg. 2025 Jul 5;58(4):134-145. doi: 10.5090/jcs.25.024.
2
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.替雷利珠单抗联合化疗对比安慰剂联合化疗用于治疗晚期或转移性食管鳞癌（RATIONALE-306）：一项全球性、随机、安慰剂对照、III 期研究。
Lancet Oncol. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0. Epub 2023 Apr 17.
3
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
4
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
5
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.纳武利尤单抗辅助治疗食管或胃食管结合部癌。
N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
6
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者（ATTRACTION-3）：一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.